PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
47.25%
G&A growth above 5% signals concerning overhead expansion. Seth Klarman would demand justification for increased costs.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.84%
Operating expenses growth above 10% signals concerning cost expansion. Seth Klarman would demand justification.
63.84%
Total costs growth above 5% signals concerning expansion. Seth Klarman would demand justification.
217.76%
Interest expense growth above 10% signals concerning debt expansion. Seth Klarman would demand justification.
No Data
No Data available this quarter, please select a different quarter.
-63.84%
Negative EBITDA growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-63.84%
Negative operating income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
63.84%
Other expenses growth above 30% signals concerning expansion. Seth Klarman would scrutinize unusual items.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
88.24%
Tax expense growth above 20% signals concerning expansion. Seth Klarman would scrutinize tax strategy.
-88.24%
Negative net income growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
-87.91%
Negative EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
-87.91%
Negative diluted EPS growth needs thorough analysis. Benjamin Graham would examine operational issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.